Breast Cancer Action Says Two New Drug Pricing Studies Miss the Mark
Tagged :
Print 
Text Size: Normal / Medium / Large
Printer-friendly versionJune 26, 2007
San Francisco, CA- Breast Cancer Action (BCA) today expressed grave concerns about the two new studies that purport to justify the exorbitantly high price of breast cancer drugs.
One of the studies looked at Herceptin-a drug that costs upwards of $40,000 a year. The other study looked at Aromasin-an aromatase inhibitor that costs more than $3000 per year in the United States .
The Canadian Women's Health Network and the Centres of Excellence for Women's Health program are financially supported by Health Canada through the Women's Health Contribution Program. The views herein do not necessarily represent the official policy of Health Canada.